177477-91-7

Upstream product

• 160648-00-0 4-(methylcarbamoyl) cinnamic acid 
• 177477-90-6 3-(N-Glycyl-N-methylamino)-1-(tert-butyldiphenyl-silyloxymethyl)-2,6-dichlorobenzene 
• 167837-47-0 N-(3-((tert-butyldiphenylsilyloxy)methyl)-2,4-dichlorophenyl)-2-(1,3-dioxoisoindolin-2-yl)-N-methylacetamide 
• 167837-46-9 N-(3-((tert-butyldiphenylsilyloxy)methyl)-2,4-dichlorophenyl)-2-(1,3-dioxoisoindol-in-2-yl)-acetamide 
• 167837-44-7 tert-butyl(2,6-dichloro-3-nitrobenzyloxy)diphenylsilane 
• 167837-45-8 3-amino-1-(tert-butyldiphenylsilyloxymethyl)-2,6-dichlorobenzene 
• 160647-01-8 2,6-Dichloro-3-nitrobenzyl alcohol 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 179627-11-3 4-(methylcarbamoyl)cinnamic acid 

Downstream Products

• 209919-52-8 FR 165649 
• 177477-93-9 2,6-dichloro-3-[N-methyl-N-[4-(methylcarbamoyl)cinnamoylglycyl)amino]benzyl bromide 
• 177477-92-8 (E)-4-((3-((2-((2,4-dichloro-3-(hydroxymethyl)phenyl)methyl)amino)-2-oxoethyl)-amino)-3-oxoprop-1-en-1-yl)-N-methylbenzamide 

Relevant academic research and scientific papers

Pyridopyrimidones, quinolines and fused N-heterocycles as bradykinin antagonists

This invention relates to a compound of the formula: STR1 wherein Z is a group of the formula: STR2 in which X1 is N or C--R1, X2 is N or C--R9, X3 is N or C--R2, R1 is lower alk

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a]pyridine moiety

Recently we reported on overcoming the species difference of our first orally active non-peptide bradykinin (BK) B2 receptor antagonists, incorporating an 8-[[3-(N-acylglycyl-N-methylamino)-2,6-dichlorobenzyl]oxy]- 3-halo-2-methylimidazo[1,2-α]